Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Landon L Chan"'
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Клинический разбор в общей медицине, Vol 5, Iss 7, Pp 24-36 (2024)
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treat
Externí odkaz:
https://doaj.org/article/6018f6404fd44328a5aec940740119bd
Autor:
Molly S.C. Li, M.B.B.S., Kirsty W.C. Lee, MBChB, Kevin K.S. Mok, MBChB, Herbert H.F. Loong, M.B.B.S., K.C. Lam, MBChB, Florence S.T. Mok, M.B.B.S., Landon L. Chan, MBChB, Y.M. Lau, M.B.B.S., K.P. Chan, MBChB, Joyce T.Y. Ng, MBChB, Wesley K.Y. Wong, M.B.B.S., Benjamin H.W. Lam, M.B.B.S., Allen C.C. Chen, BM, Matthew M.P. Lee, MBChB, Olivia H. Chen, MD, PhD, Tony S.K. Mok, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100648- (2024)
Introduction: Interstitial lung disease (ILD) is the most frequent cause of drug-related mortality from EGFR tyrosine kinase inhibitors (TKIs). Yet, for patients with symptomatic osimertinib-induced ILD, the risk of recurrent ILD associated with EGFR
Externí odkaz:
https://doaj.org/article/3e7352949ccd4e5d8d2933a594642014
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 4, Pp 909-923 (2023)
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treat
Externí odkaz:
https://doaj.org/article/8d62e67bb0b442e086f1983cd638e24c
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 2, Pp 345-348 (2023)
Externí odkaz:
https://doaj.org/article/7b9c3ac908c34b28b9adc4f5dc287112
Publikováno v:
Current Oncology, Vol 29, Iss 8, Pp 5489-5507 (2022)
Hepatocellular carcinoma (HCC) has high mortality. The option of systemic therapy has increased significantly over the past five years. Sorafenib was the first multikinase inhibitor, introduced in 2007, as a treatment option for HCC, and it was the o
Externí odkaz:
https://doaj.org/article/9b6f1eb5348344eaad2d936072fea0d6
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Liver International. 43:271-273
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbc311e9158472c280d07d4654f92869
https://doi.org/10.1111/liv.15494
https://doi.org/10.1111/liv.15494
Autor:
Charing C N Chong, Anthony W.H. Chan, Leung Li, Yat M Lau, Cheuk Man Chu, Tony Mok, Paul N. M. Cheng, Simon C.H. Yu, Angela M Liu, Kelvin K. Ng, Winnie Yeo, Stephen L. Chan, Landon L. Chan
Publikováno v:
Investigational New Drugs
Background: Pegylated recombinant human arginase (PEG-BCT-100) is an arginine depleting drug. Preclinical studies showed that HCC is reliant on exogenous arginine for growth due to the under-expression of the arginine regenerating enzymes argininosuc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af1fd93c2530989f99b6c97af45f5bcb
https://doi.org/10.1007/s10637-021-01111-8
https://doi.org/10.1007/s10637-021-01111-8
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Cancers. 14(6)
Immune checkpoint inhibitors have revolutionised the systemic treatment of advanced hepatocellular carcinoma. Although phase III trials, testing single agent nivolumab and pembrolizumab, failed to meet their primary endpoints, the combination of atez
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3173da635b0bdb8bdf83d11f6dc05e5d
https://pubmed.ncbi.nlm.nih.gov/35326677
https://pubmed.ncbi.nlm.nih.gov/35326677
Autor:
Stephen L. Chan, Landon L. Chan
Publikováno v:
Surgical Practice. 23:48-58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2b8fd4526ac33a9fb8b6e354599f067
https://doi.org/10.1111/1744-1633.12351
https://doi.org/10.1111/1744-1633.12351
Autor:
Stephen L. Chan, Landon L. Chan
Publikováno v:
Expert opinion on emerging drugs. 26(1)
Hepatocellular carcinoma (HCC) is a major challenge in oncology. It ranks fourth in most common causes of cancer death worldwide. Despite advancements in cancer treatment, limited effective treatment options exist for advanced HCC. Immune checkpoint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d05183624a90d226901914e211628af0
https://pubmed.ncbi.nlm.nih.gov/33724135
https://pubmed.ncbi.nlm.nih.gov/33724135